LKB1 modulates lung cancer differentiation and metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz-Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of epithelial cancers. Although uncommon in most sporadic cancers, inactivating somatic mutations of LKB1 have been reported in primary human lung adenocarcinomas and derivative cell lines. Here we used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 to other tumour suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (also known as Cdkn2a) in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumours demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumours lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer. These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond its role regulating metabolism via AMPK, LKB1 loss promotes tumorigenesis by reprogramming epigenetic states, facilitating lineage plasticity and promoting metastasis22,67–70.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [22]
In the citing paper
“Somatic deletion of Lkb1 is insufficient for initiation of lung carcinogenesis in mice as a singular event but dramatically accelerates KrasG12D-driven carcinogenesis and fosters early metastatic dissemination84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“In addition, loss of Lkb1 results in epigenetic reprogramming and an expanded tumor histological repertoire, with high incidence of squamous or adenosquamous carcinomas, in agreement with data supporting enrichment of LKB1 mutations in human adenosquamous NSCLC84–86.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“Loss of p53 or expression of either dominant negative or dominant gain-of-function Trp53 mutants also co-operate with oncogenic Kras to induce LUADs with shortened latency and increased metastatic proclivity, although these tumors are less aggressive than those with Lkb1 loss69–71, 84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citation
Cited by
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Autophagy in the Pathogenesis of Disease
Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
“LKB1 is also frequently mutated in sporadic cases of non-small-cell lung cance”
BackgroundAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
“In addition, LKB1 mutations occur in a large percentage (30–40%) of sporadic non small cell lung cancers (NSCLC) (Sanchez-Cespedes et al., 2002; Ji et al., 2007).”
BackgroundMetabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,389
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Non-small-cell lung cancers: a heterogeneous set of diseases
Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3775 · Cited by 1,942
Self-citationThe LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
“, in which at least 15–35% of cases have this lesio”
BackgroundSteinberg, G. R., & Kemp, B. E. (2009) · Physiological Reviews · doi:10.1152/physrev.00011.2008 · Cited by 1,637
“Since the constitutively active AMPK fragment 1 (1-312) is not activated by the PT1 compound, it is proposed that PT1 acts by reversing the autoinhibition of the AIS (313-335).”
BackgroundInfluentialAMP-activated protein kinase: an energy sensor that regulates all aspects of cell function
Hardie, D. G. (2011) · Genes & Development · doi:10.1101/gad.17420111 · Cited by 1,638
“As expected for a tumor suppressor, the STK11 gene is also frequently mutated in spontaneous cancers, including ;30% of non-small-cell lung cancers (Sanchez-Cespedes et al. 2002; Ji et al. 2007) and 20% of cervical cancers, including the cervical cancer in the patient Henrietta Lacks that gave rise to the HeLa cell li…”
BackgroundAutophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
“Moreover, somatic mutations in STK11 have been documented in a considerable percentage of squamous cell carcinomas and lung adenocarcinomas (Ji et al , 2007).”
Metabolic heterogeneity in human lung tumors
Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., Jiang, L., Ko, B., Skelton, R., Loudat, L., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.034 · Cited by 1,138
“Oncogene expression is sufficient to reprogram some aspects of nutrient utilization, suggesting that cell-autonomous metabolism is driven in part by the oncogenotype (Gao et al., 2009; Ji et al., 2007; Son et al., 2013).”
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress
Jeon, S.-M., Chandel, N. S., & Hay, N. (2012) · Nature · doi:10.1038/nature11066 · Cited by 1,132
Tumor suppressors and cell metabolism: a recipe for cancer growth
Jones, R. G., & Thompson, C. B. (2009) · Genes & Development · doi:10.1101/gad.1756509 · Cited by 1,085
“2002), and complete loss of LKB1 results in resistance to senescence and the development of aggressive cancers (Ji et al. 2007; Contreras et al. 2008; Gurumurthy et al. 2008).”
BackgroundChiang, A. C., & Massagué, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0805239 · Cited by 1,054
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Tackling the cancer stem cells — what challenges do they pose?
Pattabiraman, D. R., & Weinberg, R. A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4253 · Cited by 990
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
“This finding is consistent with prior work in GEMMs of lung adenocarcinoma initiated by somatic activation of an endogenous KrasG12D allele, whereby concomitant genetic inactivation of either Stk11/Lkb1 or Trp53 sufficed to promote fully invasive and widely metastatic lung adenocarcinoma with shortened latency and com…”
Self-citationConditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 894
“The activation of oncogenic K-ras along with loss of p16 Ink4a or Ink4a/Arf tumor suppressors, which are mutated in 20%–50% of human cases, have been describe”
BackgroundAMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control
González, A., Hall, M. N., Lin, S.-C., & Hardie, D. G. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.015 · Cited by 797
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.117 · Cited by 665
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth
Shaw, R. J. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01972.x · Cited by 644
“LKB1 mutations are found in NSCLC, which represent 85% of lung cancer, and mutation rate estimates vary between 20% and 40% depending on the study and the methodology employed for detecting LKB1 alterations (Ji et al. 2007, Hezel & Bardeesy 2008).”
BackgroundInfluentialKoyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
“Murine cell line and in vivo studies Mouse strains were described previously (3).”
Self-citationShackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585
“The mean tumor latencies we observed were comparable to previous studies with the exception of KPluc mice, which developed large, aggressive lung tumors with the same latency of KLluc mice (Jackson et al., 2005; Ji et al., 2007).”
InfluentialSchmidt, L. H., Spieker, T., Koschmieder, S., Humberg, J., Jungen, D., Bulk, E., Hascher, A., Wittmer, D., Marra, A., Hillejan, L., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307eac · Cited by 545
A mouse model for EML4-ALK -positive lung cancer
Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805381105 · Cited by 512
“It remains to be determined whether additional abnormalities in other oncogenes or tumor suppressor genes, such as KRAS or LKB1 (25, 26), may lead to the generation of metastatic tumors in EML4-ALK transgenic mice.”
BackgroundRekhtman, N., Pietanza, M. C., Hellmann, M. D., Naidoo, J., Arora, A., Won, H., Halpenny, D. F., Wang, H., Tian, S. K., Litvak, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2946 · Cited by 487
“The most striking finding was that nearly all LCNECs lacking RB1þTP53 alterations (NSCLC-like subset) harbored additional NSCLC-typemutations: STK11 and KRASmutations, typical of adenocarcinoma, occurred in 15 (60”
BackgroundInfluentialAnoikis Resistance: An Essential Prerequisite for Tumor Metastasis
Kim, Y.-N., Koo, K. H., Sung, J. Y., Yun, U.-J., & Kim, H. (2012) · International Journal of Cell Biology · doi:10.1155/2012/306879 · Cited by 461
“This aerobic glycolysis is regulated by PI3K/Akt [76, 77], hypoxia-inducible factor (HIF) [78–82], p53 [83–85], Myc [77, 86, 87], and AMPactivated protein kinase (AMPK)-liver kinase B1 (LKB1) [88–90] pathways.”
BackgroundPicking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
“Tumors with STK11/LKB1 alterations Nearly one-third of NSCLC samples harbor inactivating alterations of STK11/LKB1 (16), which are known to frequently coexist with KRASmutations, and are thought to play an important role in progression to metastasis (17, 18).”
BackgroundArbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466
“Preclinical data have suggested that loss of STK11 leads to a more aggressive tumor phenotype (21).”
BackgroundAMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
Hardie, D. G. (2013) · Diabetes · doi:10.2337/db13-0368 · Cited by 458
“In these mice, expression of mutant K-Ras alone causes some tumors, but combination with loss of p53 or LKB1 increases the multiplicity of tumors and metastasis (74).”
BackgroundLou, Y., Diao, L., Cuentas, E. R. P., Denning, W. L., Chen, L., Fan, Y. H., Byers, L. A., Wang, J., Papadimitrakopoulou, V. A., Behrens, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1434 · Cited by 438
Self-citationControl of autophagy by oncogenes and tumor suppressor genes
Maiuri, M. C., Tasdemir, E., Criollo, A., Morselli, E., Vicencio, J. M., Carnuccio, R., & Kroemer, G. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.131 · Cited by 435
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446
Self-citationCrosstalk Between Mammalian Autophagy and the Ubiquitin-Proteasome System
Kocaturk, N. M., & Gozuacik, D. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00128 · Cited by 419
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer
Liu, G., Pei, F., Yang, F., Li, L., Amin, A., Liu, S., Buchan, J., & Cho, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020367 · Cited by 425
“The mutation or deletion of LKB1, a serine/threonine master kinase, has been found in NSCLC, which may cause loss of its tumor-suppressor function and promote tumor growth via the LKB1/AMPK/mTOR pathway [100,120,121].”
BackgroundSchabath, M. B., Welsh, E. A., Fulp, W. J., Chen, L., Teer, J. K., Thompson, Z. J., Engel, B. E., Xie, M., Berglund, A. E., Creelan, B. C., et al. (2016) · Oncogene · doi:10.1038/onc.2015.375 · Cited by 416
“Indeed, mouse studies demonstrate acceleration of KRAS induced tumorigenesis and increased metastasis in the presence of concurrent STK11 null mutations (19).”
Self-citationMetformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
Memmott, R. M., Mercado, J. R., Maier, C. R., Kawabata, S., Fox, S. D., & Dennis, P. A. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0055 · Cited by 408
Unravelling the complexity of metastasis — molecular understanding and targeted therapies
Sethi, N., & Kang, Y. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3125 · Cited by 397
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Xu, C., Fillmore, C. M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 391
“Wepreviously reported that simultaneous activation of Kras(Kras) and inactivation of Lkb1 (also known as serine-threonine kinase 11 [Stk11]) in the lung gave rise to multiple lung cancer histologies, including SCCs (Ji et al., 2007); however, KRASmutations are very rarely found in human squamous lung tumors.”
BackgroundInfluentialSelf-citationTrujillo, J. A., Sweis, R. F., Bao, R., & Luke, J. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0277 · Cited by 393
“The serine/threonine liver kinase B1 (LKB1; also known as STK11) is a tumor suppressor gene mutated in a diverse range of cancer types, and LKB1 loss has been associated with worse prognosis in several cancer types (47, 48).”
BackgroundImportant role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., Mcburnie, W., Fleming, S., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20080557 · Cited by 396
Anti- and pro-tumor functions of autophagy
Morselli, E., Galluzzi, L., Kepp, O., Vicencio, J.-M., Criollo, A., Maiuri, M. C., & Kroemer, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.01.006 · Cited by 375
“Activates AMPK and hence TSC2 May also stimulate autophagy by stabilizing p27 [22,23]”
BackgroundAkt-dependent and -independent mechanisms of mTOR regulation in cancer
Memmott, R. M., & Dennis, P. A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.004 · Cited by 382
AMPK As a Metabolic Tumor Suppressor: Control of Metabolism and Cell Growth
Luo, Z., Zang, M., & Guo, W. (2010) · Future Oncology · doi:10.2217/fon.09.174 · Cited by 383
“In addition, somatic mutations of the LKB1 gene have been found in several other cancers, for example, in approximately 34% of lung adenocarcinomas, 19% of squamous cell carcinomas and 20% of cervical carcinomas and other cancers [27–30].”
BackgroundStructure of the LKB1-STRAD-MO25 Complex Reveals an Allosteric Mechanism of Kinase Activation
Zeqiraj, E., Filippi, B. M., Deak, M., Alessi, D. R., & van Aalten, D. M. F. (2009) · Science · doi:10.1126/science.1178377 · Cited by 365
Genetic alterations defining NSCLC subtypes and their therapeutic implications
Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.025 · Cited by 375
Zheng, B., Jeong, J. H., Asara, J. M., Yuan, Y.-Y., Granter, S. R., Chin, L., & Cantley, L. C. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.026 · Cited by 359
“, 2002), and its inactivation in the mouse promotes development of metastatic lung adenocarcinomas (Ji et al., 2007).”
BackgroundLKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348
Self-citationMetabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 328
Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution
Yang, D., Jones, M. G., Naranjo, S., Rideout, W. M., Min, K. H. (., Ho, R., Wu, W., Replogle, J. M., Page, J. L., Quinn, J. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.015 · Cited by 334
“Both genes have been studied extensively in both human and mouse models and appear to regulate progression through distinct mechanisms (Ji et al., 2007; Carretero et al., 2010; Nguyen et al., 2009; Hollstein et al., 2019; Tammela et al., 2017; Murray et al., 2019; Kerk et al., 2021; Parsons et al., 2021).”
Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 335
Self-citationCPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
Kim, J., Hu, Z., Cai, L., Li, K., Choi, E., Faubert, B., Bezwada, D., Rodriguez-Canales, J., Villalobos, P., Lin, Y.-F., et al. (2017) · Nature · doi:10.1038/nature22359 · Cited by 325
LKB1 and AMPK and the cancer-metabolism link - ten years after
Hardie, D. G., & Alessi, D. R. (2013) · BMC Biology · doi:10.1186/1741-7007-11-36 · Cited by 301
“Such mutations are now estimated to occur in approximately 30% of non-small cell lung cancers [64,65], approximately 20% of cervical cancers [66], and approximately 10% of cutaneous melanomas [67].”
BackgroundZhang, W., Gao, Y., Li, P., Shi, Z., Guo, T., Li, F., Han, X., Feng, Y., Zheng, C., Wang, Z., et al. (2014) · Cell Research · doi:10.1038/cr.2014.10 · Cited by 296
Self-citationZhao, X., Zmijewski, J. W., Lorne, E., Liu, G., Park, Y.-J., Tsuruta, Y., & Abraham, E. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90210.2008 · Cited by 301
A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
Mohseni, M., Sun, J., Lau, A., Curtis, S., Goldsmith, J., Fox, V. L., Wei, C., Frazier, M., Samson, O., Wong, K.-K., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2884 · Cited by 294
Self-citationCompromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290
“We also studied mice with lung-specific conditional activating Kras and inactivating p53 mutations that develop highly aggressive lung adenocarcinomas with short latency compared to those driven by Kras G12D alone 28,31 .”
Self-citationLysyl Oxidase, Extracellular Matrix Remodeling and Cancer Metastasis
Xiao, Q., & Ge, G. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0105-z · Cited by 276
“Lung adenocarcinoma R: ↑ C [116]”
Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides
Villa, E., Ali, E., Sahu, U., & Ben-Sahra, I. (2019) · Cancers · doi:10.3390/cancers11050688 · Cited by 281
“Interestingly, inactivation of LKB1 is often accompanied by mutations in the RAS-RAF pathway in human cancers [82].”
BackgroundAMP ‐activated protein kinase: a key regulator of energy balance with many roles in human disease
Grahame Hardie, D. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12268 · Cited by 285
Somatic LKB1 Mutations Promote Cervical Cancer Progression
Wingo, S. N., Gallardo, T. D., Akbay, E. A., Liang, M.-C., Contreras, C. M., Boren, T., Shimamura, T., Miller, D. S., Sharpless, N. E., Bardeesy, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005137 · Cited by 247
“It is also notable that Lkb1 loss in the lung was associated with a broad histologic spectrum (squamous cell carcinomas to adenocarcinomas), recalling that LKB1 inactivation characterizes cervical carcinomas of varied histologic subtypes [9].”
BackgroundResultSelf-citationLoss of the Tumor Suppressor LKB1 Promotes Metabolic Reprogramming of Cancer Cells via HIF-1α
Faubert, B., Vincent, E. E., Griss, T., Samborska, B., Izreig, S., Svensson, R. U., Mamer, O. A., Avizonis, D., Shackelford, D. B., Shaw, R. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312570111 · Cited by 278
Lelièvre, P., Sancey, L., Coll, J.-L., Deniaud, A., & Busser, B. (2020) · Cancers · doi:10.3390/cancers12123594 · Cited by 271
“LOXL1 + Cell lines Lung Adenocarcinoma [88]”
Deciphering the cells of origin of squamous cell carcinomas
Sánchez-Danés, A., & Blanpain, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0024-5 · Cited by 261
AMPK signaling and its targeting in cancer progression and treatment
Hsu, C.-C., Peng, D., Cai, Z., & Lin, H.-K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.006 · Cited by 246
Gatza, M. L., Silva, G. O., Parker, J. S., Fan, C., & Perou, C. M. (2014) · Nature Genetics · doi:10.1038/ng.3073 · Cited by 258
Self-citationYu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2961 · Cited by 259
“For example, within KRAS-mutant lung cancers, concurrent LKB1 (STK11) and TP53 mutations may be associated with shorter survival [6-9] and the presence of the former may also confer a greater sensitivity to mTOR or MEK inhibition [10, 11].”
BackgroundMolecular Biology of Lung Cancer: Clinical Implications
Larsen, J. E., & Minna, J. D. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.003 · Cited by 245
Carretero, J., Shimamura, T., Rikova, K., Jackson, A. L., Wilkerson, M. D., Borgman, C. L., Buttarazzi, M. S., Sanofsky, B. A., McNamara, K. L., Brandstetter, K. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.026 · Cited by 243
“Lastly, and as shown on Figure S1B, the repressed component of the Mets signature showed a strong and significant correlation with the human samples that are mutant for both KRAS and LKB1 in the University of North Carolina dataset (Ji et al., 2007).”
BackgroundMethodInfluentialSelf-citationEpidemiology of cancer of the small intestine
Pan, S. Y. (2011) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v3.i3.33 · Cited by 232
LKB1; linking cell structure and tumor suppression
Hezel, A. F., & Bardeesy, N. (2008) · Oncogene · doi:10.1038/onc.2008.342 · Cited by 228
Self-citationPrimary Cilia and the Cell Cycle
Plotnikova, O. V., Pugacheva, E. N., & Golemis, E. A. (2009) · Methods in Cell Biology · doi:10.1016/s0091-679x(08)94007-3 · Cited by 236
“In future experiments, it may also be interesting to consider that GSK3β is regulated by Lkb1, a tumor suppressor that influences cell cycle and cell polarity (Green, 2004), and regulates expression of HEF1/NEDD9 (Ji et al., 2007), the Aurora-A activator (Pugacheva et al., 2007).”
BackgroundInfluentialLKB1 and AMPK Family Signaling: The Intimate Link Between Cell Polarity and Energy Metabolism
Jansen, M., ten Klooster, J. P., Offerhaus, G. J., & Clevers, H. (2009) · Physiological Reviews · doi:10.1152/physrev.00026.2008 · Cited by 221
“In contrast, recent research now shows that LKB1 is frequently targeted for inactivation in sporadic pulmonary cancers, in particular its most frequent subtype adenocarcinoma (56, 79, 97).”
BackgroundAn integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
Chitale, D., Gong, Y., Taylor, B. S., Broderick, S., Brennan, C., Somwar, R., Golas, B., Wang, L., Motoi, N., Szoke, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.135 · Cited by 230
“LKB1 cooperates with mutant KRAS in mouse lung tumorigenesis (Ji et al., 2007).”
InfluentialPhosphorylation by Akt within the ST loop of AMPK-α1 down-regulates its activation in tumour cells
Hawley, S. A., Ross, F. A., Gowans, G. J., Tibarewal, P., Leslie, N. R., & Hardie, D. G. (2014) · Biochemical Journal · doi:10.1042/bj20131344 · Cited by 215
“Indeed, somatic loss-of-function mutations in the gene encoding LKB1 ( STK11 ) occur in approximately 30 % of non-small-cell lung cancers [21,22] and 20 % of cervical cancers [23].”
Richardson, A. M., Havel, L. S., Koyen, A. E., Konen, J. M., Shupe, J., Wiles, W. G., Martin, W. D., Grossniklaus, H. E., Sica, G., Gilbert-Ross, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1776 · Cited by 227
“Vimentin-null mice have reduced metastatic disease and less focal invasion The KLVþ/þ model develops robust primary lung tumors and metastasis to the mediastinal lymph node (15, 18).”
BackgroundMethodInfluentialPathogenesis of lung cancer signalling pathways: roadmap for therapies
Brambilla, E., & Gazdar, A. (2009) · European Respiratory Journal · doi:10.1183/09031936.00014009 · Cited by 205
“STK11 is a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation of cell polarity and metastasis [78].”
BackgroundMolecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
“Another study found inactivation of LKB1 in 34% and 19% of 144 human lungs in AC and SQCC, respectively [169].”
BackgroundEvidence That SOX2 Overexpression Is Oncogenic in the Lung
Lu, Y., Futtner, C., Rock, J. R., Xu, X., Whitworth, W., Hogan, B. L. M., & Onaitis, M. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011022 · Cited by 212
“Inducible deletion of the tumor suppressor Lkb1 along with inducible expression of oncogenic K-Ras leads to adenocarcinoma with squamous features [27] as well.”
BackgroundCharacterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
Liu, Q., Xu, C., Kirubakaran, S., Zhang, X., Hur, W., Liu, Y., Kwiatkowski, N. P., Wang, J., Westover, K. D., Gao, P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1702 · Cited by 212
“The mice were imaged by Magnetic resonance imaging (MRI) biweekly to determine the reduction in tumor volume during the respective treatments as described previously(35).”
MethodSelf-citationmTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C.-L., Vera, D. R., & Shaw, R. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900465106 · Cited by 205
In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer
Momcilovic, M., Jones, A., Bailey, S. T., Waldmann, C. M., Li, R., Lee, J. T., Abdelhady, G., Gomez, A., Holloway, T., Schmid, E., et al. (2019) · Nature · doi:10.1038/s41586-019-1715-0 · Cited by 214
Zhang, M., Yang, W., Wang, P., Deng, Y., Dong, Y.-T., Liu, F.-F., Huang, R., Zhang, P., Duan, Y.-Q., Liu, X.-D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19973-6 · Cited by 207
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
Hezel, A. F., Deshpande, V., & Zhu, A. X. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4787 · Cited by 210
“STK11, a key regulator of metabolism and cellular polarity, is frequently mutated in non–small-cell lung cancer (NSCLC) and less frequently mutated in pancreatic cancers.(64,65)”
BackgroundNaidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211
“In KRAS-mutant tumors, the presence of a concurrent liver kinase B1 (serine/ threonine kinase 11) mutation portends a poor prognosis, and may confer resistance to targeted therapies such as mammalian target of rapamycin (mTOR) and mitogenactivated protein kinase (MEK) kinase inhibition.(31-37) Two of our 3 patients wi…”
BackgroundMolecular biology of lung cancer: Clinical implications
Fong, K. M., & Minna, J. D. (2002) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00062-5 · Cited by 209
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J. H., Gao, Y., Cheng, K. A., Cohoon, T. J., Qi, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3904 · Cited by 202
“(G12D) at the endogenous Kras locus, conditional Lkb1 knockout, and conditional p53 knockout have been described previously (21, 23).”
BackgroundMethodSelf-citationMetabolic Diversity in Human Non-Small Cell Lung Cancer Cells
Chen, P.-H., Cai, L., Huffman, K., Yang, C., Kim, J., Faubert, B., Boroughs, L., Ko, B., Sudderth, J., McMillan, E. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.028 · Cited by 212
Tumor Suppression and Promotion by Autophagy
Ávalos, Y., Canales, J., Bravo-Sagua, R., Criollo, A., Lavandero, S., & Quest, A. F. G. (2014) · BioMed Research International · doi:10.1155/2014/603980 · Cited by 196
Critical role of AMPK in redox regulation under glucose starvation
Ren, Y., & Shen, H.-M. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101154 · Cited by 193
Kim, S. M., Nguyen, T. T., Ravi, A., Kubiniok, P., Finicle, B. T., Jayashankar, V., Malacrida, L., Hou, J., Robertson, J., Gao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1215 · Cited by 199
“E) Dextran uptake in A549 (LKB1-/-, KRAS G12S) ± Compound C (10 µM).”
BackgroundInfluentialGenetic Changes in Squamous Cell Lung Cancer: A Review
Heist, R. S., Sequist, L. V., & Engelman, J. A. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824cc334 · Cited by 191
“Genomic alterations in LKB1 was found in 34% adenocarcinomas and 19% squamous cell carcinomas in one study of NSCLCs, with most of these being single copy mutations or deletions.(108) Mutations in LKB1 were detected in 11% of lung cancers tested, and more commonly in adenocarcinomas (13%) versus squamous (5%).”
BackgroundCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07943-7 · Cited by 194
“Inactivation of several TSGs—including Stk11 and, to a lesser extent, Keap1 —promoted in vivo tumour growth in the absence of therapy, as reported previously 33–35 (Extended Data Fig.”
Self-citationFan, C., Prat, A., Parker, J. S., Liu, Y., Carey, L. A., Troester, M. A., & Perou, C. M. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-3 · Cited by 192
“(2) 77 modules were represented as the first Principal Component of previously published gene lists [3,8-10,12, 13,15,19,20,22,23,25,27-32,34,36,37,40,56-66] that showed heterogeneous expression patterns (i.”
BackgroundSelf-citationMCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
Qian, Y., Galan-Cobo, A., Guijarro, I., Dang, M., Molkentine, D., Poteete, A., Zhang, F., Wang, Q., Wang, J., Parra, E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.015 · Cited by 193
Self-citationTransdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma
Han, X., Li, F., Fang, Z., Gao, Y., Li, F., Fang, R., Yao, S., Sun, Y., Li, L., Zhang, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms4261 · Cited by 193
Self-citationcAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth
Chen, Z., Li, J.-L., Lin, S., Cao, C., Gimbrone, N. T., Yang, R., Fu, D. A., Carper, M. B., Haura, E. B., Schabath, M. B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85250 · Cited by 194
“LKB1 loss was found to promote lung cancer metastasis in a KRAS mouse model of NSCLC (13).”
Background
Metadata
- Authors
- Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- ORCID
- Ji, Hongbin
- Ramsey, Matthew R.
- Hayes, D. Neil
- Wu, Michael C.
- Shimamura, Takeshi
- Perera, Samanthi A.
- Liang, Mei-Chih
- Bao, Lei
- Chen, Liang
- Koivunen, Jussi
- Chirieac, Lucian R.
- Padera, Robert F.
- Bronson, Roderick T.
- Lindeman, Neal I.
- Christiani, David C.
- Lin, Xihong
- Shapiro, Geoffrey I.
- Johnson, Bruce E.
- Meyerson, Matthew
- Kwiatkowski, David J.
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- Venue
- Nature
- Published
- 2007-08-05
- Volume
- 448
- Issue
- 7155
- Pages
- 807-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2134964552
- Cited by
- 1,064
- References
- 36
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 44 · 2023: 66 · 2022: 50 · 2021: 71 · 2020: 51 · 2019: 66 · 2018: 61 · 2017: 56 · 2016: 54 · 2015: 72 · 2014: 83 · 2013: 65 · 2012: 52
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- LKB1, STK11, lung cancer, tumour suppressor, metastasis, squamous cell carcinoma, non-small cell lung cancer, KRAS, p53, Ink4a/Arf, CDKN2A, tumor differentiation, Peutz-Jeghers syndrome, metastasis-promoting genes
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Metastasis, Genes, ras, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Genes, p53, Protein Serine-Threonine Kinases, Genes, p16, Gene Expression Profiling, Cell Line, Tumor, Mice, Genes, Neoplasm, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.